New Treatment for Breakthrough Cancer Pain Accepted for Use in Scotland

19-Jan-2011 - Archimedes Pharma Ltd announced the decision by the Scottish Medicines Consortium (SMC) to accept PecFent® (fentanyl pectin nasal spray) for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for ...

Archimedes Pharma Receives European Marketing Authorisation for PecFent for the Treatment of Breakthrough Cancer Pain

03-Sep-2010 - Archimedes Pharma Ltd. announced that the European Commission has granted marketing authorisation for its lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer ...

Archimedes Pharma announces major fundraising of £65 million

Appoints new Chief Executive Officer to accelerate growth of transatlantic business

03-Mar-2010 - Archimedes Pharma announced that it has raised £65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. ...

Archimedes Pharma wins the Scrip Award for SME Pharma Company of the Year

24-Nov-2009 - Archimedes Pharma Limited won the Scrip Award SME Pharma Company of the Year. The Scrip Awards are voted for by a panel of esteemed judges from the pharmaceutical industry worldwide. The judging criteria included: excellent performance across a range of activities, such as a growth in revenue or ...

Archimedes Pharma enters partnership with Almac Discovery to develop product to treat chemotherapy-induced nausea and vomiting

16-Jun-2009 - Archimedes Pharma Limited announced that its development organisation, Archimedes Development Limited has signed a global licensing and development agreement with Almac Discovery Limited to develop a novel intranasal granisetron product. This product, which uses Archimedes’ proprietary ChiSys ...

Archimedes Pharma announces ground breaking phase III data for NasalFent

First study of a next generation fentanyl based product to show superiority over immediate release morphine

11-May-2009 - Archimedes Pharma Limited announced new positive headline phase III results for NasalFent®, the Company’s highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release ...

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects

Phase II trials on both projects to be initiated during 2009

02-Mar-2009 - Archimedes Pharma Limited announced positive headline data from its recently completed proof-of-concept trials for two of its intranasal (IN) development projects. Both the IN Apomorphine and IN Diazepam Phase I studies showed high bioavailability, positive pharmacokinetics and good tolerability ...

Archimedes Pharma: First Positive Phase III Clinical Trial Results for NasalFent

Shows Significant Difference in Pain Within 5 Minutes of Dosing

13-Oct-2008 - Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, announces positive headline Phase III results for NasalFent®, the Company’s innovative fentanyl citrate nasal spray, developed to provide fast, effective and convenient treatment for breakthrough cancer ...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent

12-Jun-2007 - Archimedes Pharma Ltd presented new clinical data from a Phase II study of Nasalfent(r), an fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain. Data were presented at the 10th Congress of the European Association for Palliative ...

Archimedes Pharma Enrols First Patient in Phase III Programme for Nasalfent in Cancer Pain

01-Feb-2007 - Archimedes Pharma Ltd announced the commencement of its global Phase III programme for Nasalfent® in breakthrough cancer pain. Up to 180 patients are being recruited in a placebo controlled, randomised trial across 43 centres in the US and Canada. The endpoints will focus on assessments of pain ...